obesity drug news today glp-1 2025 oct 27 Weight loss with medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans: Cell Reports Medicine Medicare $50 GLP-1 Weight Loss

Abstract Objective To evaluate the comparative efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on glycaemic control, body weight, and lipid profile in adults with type 2 diabetes

Secondly, we combined data from trials that varied in duration, baseline characteristics, and types of AOMs, which might result in heterogeneity to the meta-analysis, so we used a random-effects model for statistical analysis

North America led the market by securing a market share of 49.7% in 2024

In 2018, a 39 amino-acid peptide tirzepatide (LY3298176) was developed, which is similar in size to both GLP-1 and GIP with exenatide-derived C-terminal tail and thus has a prolonged half-life

Some individuals report using smaller doses to stretch prescriptions and lower monthly spending, making GLP-1 cost a key factor in why microdosing is discussed

The impact on glycaemic management is most significant for diabetics (either type 1 or 2) who require insulin given most of the carbohydrates in clear fluids are simple sugars